BRPI0519626A2 - mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse - Google Patents

mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse

Info

Publication number
BRPI0519626A2
BRPI0519626A2 BRPI0519626-4A BRPI0519626A BRPI0519626A2 BR PI0519626 A2 BRPI0519626 A2 BR PI0519626A2 BR PI0519626 A BRPI0519626 A BR PI0519626A BR PI0519626 A2 BRPI0519626 A2 BR PI0519626A2
Authority
BR
Brazil
Prior art keywords
protein
content
contaminants
composition
cell culture
Prior art date
Application number
BRPI0519626-4A
Other languages
English (en)
Inventor
Anne Charlotte Arentsen
Daniel E Rasmussen
Are Bogsnes
Arne Staby
Haleh Ahmadian
Susanne Bang
Janus Krarup
Thomas Budde Hansen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0519626A2 publication Critical patent/BRPI0519626A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes

Abstract

MÉTODOS PARA A REDUÇçO DO TEOR DE UM OU MAIS CONTAMINANTES, DO TEOR DE PROTEÍNA S EM UMA COMPOSIÇçO, DO TEOR DE UM OU MAIS CONTAMINANTES DE PROTEÍNA EM UM SOBRENADANTE DE CULTURA DE CÉLULA, DO TEOR DE PROTEÍNA 5 EM UM SOBRENADANTE DE CULTURA DE CÉLULA, COMPOSIÇçO COMPREENDENDO UMA PROTEÍNA DEPENDENTE DE VITAMINA K DE INTERESSE. A invenção refere-se a composições de proteína dependentes de vitamina K tendo um teor muito baixo, ou negligível, de contaminantes de proteína. A presente invenção também se refere a método aplicável na preparação de tais composições de proteínas dependentes de vitamina K. Tais métodos poderão ser utilizados sozinhos ou em combinação seqúencial, com a finalidade de reduzir o teor relativo de contaminantes de proteína. A presente invenção é especialmente relevante na preparação de composições de fatores de coagulação escolhidos de polipeptídeos do fator X (FX/FXa), polipeptídeos do fator IX (FIX/FIXa), polipeptídeos do fator VII (FVII/FVIIa) e a proteína C anticoagulante, especialmente os polipeptideos do fator VII.
BRPI0519626-4A 2004-12-23 2005-12-23 mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse BRPI0519626A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200402008 2004-12-23
PCT/EP2005/057145 WO2006067230A1 (en) 2004-12-23 2005-12-23 Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest

Publications (1)

Publication Number Publication Date
BRPI0519626A2 true BRPI0519626A2 (pt) 2009-02-25

Family

ID=36168465

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519626-4A BRPI0519626A2 (pt) 2004-12-23 2005-12-23 mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse

Country Status (13)

Country Link
US (1) US9187549B2 (pt)
EP (2) EP2360171A1 (pt)
JP (2) JP2008525381A (pt)
KR (2) KR20130128013A (pt)
CN (1) CN101098883B (pt)
AU (1) AU2005318106B2 (pt)
BR (1) BRPI0519626A2 (pt)
CA (1) CA2592054A1 (pt)
ES (1) ES2395544T3 (pt)
MX (1) MX2007007356A (pt)
PL (1) PL1831242T3 (pt)
RU (1) RU2460735C2 (pt)
WO (1) WO2006067230A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2592054A1 (en) 2004-12-23 2006-06-29 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
US7696318B2 (en) 2005-07-13 2010-04-13 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
AT502691A1 (de) * 2005-10-24 2007-05-15 Univ Fuer Weiterbildung Krems Extrakorporales blut- oder plasmareinigungssystem
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
GB0710321D0 (en) 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
ATE503763T1 (de) * 2007-07-11 2011-04-15 Novo Nordisk As Aufreinigung von faktor viii unter verwendung eines mixed-mode oder multimodalen harzes
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
JP5788803B2 (ja) * 2008-12-02 2015-10-07 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ポリペプチド精製
FR2946348B1 (fr) * 2009-06-05 2011-08-05 Lab Francais Du Fractionnement Procede de preparation d'une composition de complexe prothrombique a haut degre de purete
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
PL3715356T3 (pl) 2009-12-18 2024-03-11 Csl Limited Sposób oczyszczania polipeptydów
RU2012133474A (ru) 2010-01-18 2014-02-27 Ново Нордиск Хелс Кеа Аг Очистка факторов свертывания крови
WO2011121020A1 (en) * 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
KR101780518B1 (ko) * 2010-04-29 2017-09-21 박스알타 인코퍼레이티드 음이온 교환 수지상에서의 2가 양이온 결합 단백질의 정제 방법
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
CN102161701A (zh) * 2011-01-28 2011-08-24 上海兴迪金生物技术有限公司 从细胞培养液或血浆组分中分离纯化高纯度活化凝血七因子的方法
JP2011172602A (ja) * 2011-06-15 2011-09-08 Jcr Pharmaceuticals Co Ltd 組換え体ヒトｆｓｈの製造方法
EP2748180B1 (en) * 2011-10-14 2018-08-15 Baxalta GmbH Protein purification by anion exchange chromatography
AU2012322948B2 (en) * 2011-10-14 2014-11-06 Takeda Pharmaceutical Company Limited Protein purification by anion exchange chromatography
AU2014230101B2 (en) 2013-03-15 2018-04-19 Takeda Pharmaceutical Company Limited Purification method for vitamin K dependent proteins by anion exchange chromatography
WO2014181549A1 (ja) 2013-05-10 2014-11-13 株式会社デンソー 燃料噴射制御装置および燃料噴射システム
JP5750471B2 (ja) * 2013-05-22 2015-07-22 Ｊｃｒファーマ株式会社 組換え体ヒトｆｓｈの製造方法
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
WO2018165933A1 (zh) * 2017-03-16 2018-09-20 深圳先进技术研究院 调节糖代谢的多肽及其用途
KR102432962B1 (ko) * 2017-03-16 2022-08-12 쉔첸 인스티튜트스 오브 어드밴스드 테크놀로지 에너지 대사를 조절하는 폴리펩티드 및 그 용도
EP3590528A1 (en) * 2018-07-06 2020-01-08 Octapharma AG Fx activation process and its use in the preparation of a fxa composition
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
EP0118256B1 (en) * 1983-03-04 1992-05-13 Scripps Clinic And Research Foundation Immunoadsorbent, and method of recovering vitamin-k dependent protein therewith
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
JPH0759600B2 (ja) * 1986-12-15 1995-06-28 帝人株式会社 ヒト・プロテインｓに対するモノクローナル抗体
JPH01231893A (ja) * 1988-03-14 1989-09-18 Fuji Yakuhin Kogyo Kk 抗ヒトプロテインｓモノクローナル抗体およびその利用
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
AT402261B (de) * 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
AU678987B2 (en) * 1992-08-27 1997-06-19 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DK38293D0 (da) * 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
DE4342132C1 (de) 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE4406515C1 (de) * 1994-02-28 1995-10-19 Immuno Ag Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
GB9519197D0 (en) 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
US6117996A (en) 1995-09-20 2000-09-12 Novo Nordisk A/S Triazine based ligands and use thereof
JP3745805B2 (ja) * 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP2000143692A (ja) * 1998-11-11 2000-05-26 Fujimori Kogyo Co Ltd モノクローナル抗体によって精製されたトロンビン基質または阻害剤の精製方法
JP4732590B2 (ja) 1999-03-15 2011-07-27 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１及び近縁ペプチドのイオン交換クロマトグラフィー分離
WO2001004287A1 (en) 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
SE0000675D0 (sv) * 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
JP2001247599A (ja) * 2000-03-07 2001-09-11 Fujimori Kogyo Co Ltd ポリペプチド、それを用いた血液凝固因子吸着体、該吸着体を用いた血液凝固因子の精製方法、および該ポリペプチドを含有する血栓形成予防剤
US6952212B2 (en) 2000-03-24 2005-10-04 Telefonaktiebolaget Lm Ericsson (Publ) Frame decimation for structure from motion
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
AU8755001A (en) * 2000-09-13 2002-03-26 Novo Nordisk As Human coagulation factor vii variants
HUP0301245A3 (en) * 2000-10-02 2005-12-28 Novo Nordisk Healthcare Ag Tmethod for the production of vitamin k-dependent proteins
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
RU2321633C2 (ru) * 2001-02-16 2008-04-10 Ново Нордиск Хелт Кэр Аг Способ получения витамин к-зависимых белков
RU2338752C2 (ru) 2001-03-22 2008-11-20 Ново Нордиск Хелт Кэр Аг Производные фактора vii свертывания крови
JP4537059B2 (ja) 2001-09-27 2010-09-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
JP4351049B2 (ja) 2001-10-02 2009-10-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核細胞中で組換えタンパク質を生産する方法
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
NZ536340A (en) 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
US20050131005A1 (en) 2002-04-30 2005-06-16 Jiabing Wang 4-azasteroid derivatives as androgen receptor modulators
EP1908782B1 (en) 2002-09-25 2010-01-06 Novo Nordisk Health Care AG Human coagulation factor VII polypeptides
AU2003266931B2 (en) 2002-09-30 2010-01-21 Bayer Healthcare Llc FVII or FVIIa variants having increased clotting activity
CA2592054A1 (en) 2004-12-23 2006-06-29 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest

Also Published As

Publication number Publication date
AU2005318106B2 (en) 2011-11-03
JP5866274B2 (ja) 2016-02-17
MX2007007356A (es) 2007-08-14
US20080207880A1 (en) 2008-08-28
JP2013100300A (ja) 2013-05-23
CN101098883A (zh) 2008-01-02
JP2008525381A (ja) 2008-07-17
KR101364001B1 (ko) 2014-02-17
CA2592054A1 (en) 2006-06-29
US9187549B2 (en) 2015-11-17
KR20070100732A (ko) 2007-10-11
AU2005318106A1 (en) 2006-06-29
KR20130128013A (ko) 2013-11-25
CN101098883B (zh) 2013-01-23
RU2460735C2 (ru) 2012-09-10
EP1831242A1 (en) 2007-09-12
WO2006067230A1 (en) 2006-06-29
EP1831242B1 (en) 2012-09-26
RU2007122413A (ru) 2009-01-27
EP2360171A1 (en) 2011-08-24
ES2395544T3 (es) 2013-02-13
PL1831242T3 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
BRPI0519626A2 (pt) mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse
Hrženjak et al. Fibrinolytic and anticoagulative activities from the earthworm Eisenia foetida
Sharma et al. Unveiling the complexities of Daboia russelii venom, a medically important snake of India, by tandem mass spectrometry
Jo et al. Purification and characterization of a novel anticoagulant peptide from marine echiuroid worm, Urechis unicinctus
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
DE60238249D1 (de) Canolaproteinisolat-funktion i
AR037909A1 (es) Composiciones de formulaciones para lactantes que comprenden cantidades incrementadas de alfa-lactalbumina
IL217489A (en) U-pa polypeptides with specific substrate activity or activity and preparations and uses based on these polypeptides
FR2969142B1 (fr) Methode de cimentation a temperature ambiante de cendres volantes a faible teneur en calcium
NO20064584L (no) Tetrahydropyridoindolderivater
Debono et al. Clinical implications of differential antivenom efficacy in neutralising coagulotoxicity produced by venoms from species within the arboreal viperid snake genus Trimeresurus
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
BRPI0711767B8 (pt) composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante
ATE534290T1 (de) Apparat zur verlängerung der überlebensdauer von blutplättchen
UY31209A1 (es) Uso de homo y copolimeros para la estabilización de formulaciones de principios activos
BR112015023425A2 (pt) método e composição para coloração e processamento de uma amostra de urina
NO20091441L (no) Rekonstituerte surfaktanter med forbedrede egenskaper
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
EA201190286A1 (ru) Адъювантные композиции, содержащие неионный агент, обеспечивающий изотоничность
Salazar et al. Hemostatic and toxinological diversities in venom of Micrurus tener tener, Micrurus fulvius fulvius and Micrurus isozonus coral snakes
Sartim et al. Moojenactivase, a novel pro-coagulant PIIId metalloprotease isolated from Bothrops moojeni snake venom, activates coagulation factors II and X and induces tissue factor up-regulation in leukocytes
Seneci et al. A clot twist: extreme variation in coagulotoxicity mechanisms in Mexican neotropical rattlesnake venoms
Vejayan et al. Comparative analysis of the venom proteome of four important Malaysian snake species
HK1083296A1 (en) Enteral composition for the prevention and/or treatment of sepsis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO SOLICITADA ATRAVES DA PETICAO NO 870180131039 DE 17/09/2018.